Navigation Links
New Therapeutic Target Identified In Inherited Brain Tumor Disorder

l outcomes data among ARV-treated adults in Botswana.

"These results underscore the importance of monitoring not only clinical outcomes, but also ARV drug tolerability and toxicity as well," said William Wester, M.D., lead author of the article and research associate, Department of Immunology and Infectious Disease at HSPH. "Patients will respond to ARV therapy, but especially early on in their ARV treatment course, drug toxicity may significantly affect ones' quality of life and drug adherence rates." Results from the study have led to changes in the drug regimen to improve patients' drug adherence and prognosis.

In addition to creating the first public sector ARV clinic, Harvard has used the grant received in 2000 through the Secure the Future program to:

Ø Help build the initial HIV Reference Laboratory in Botswana; and

Ø Initiate the groundbreaking "Adult Antiretroviral Treatment and Drug Resistance Study to examine the three main reasons patients fail ARV therapy: drug resistance, tolerability and adherence. This study is also called the "Tshepo" Study, "Tshepo" is the word for "hope" in Setswana. This study was recently extended through 2007, making it the largest and longest running adult ARV treatment research study in the region.


'"/>

Source: Washington University School of Medicine


Page: 1 2

Related biology news :

1. Therapeutic prospects beyond Vioxx
2. Therapeutic role found for carbon monoxide
3. Novel Enzyme Shows Potential As An Anti-HIV Target
4. First-ever Compounds To Target Only Metastatic Cells Are Highly Effective Against Breast, Prostate, And Colon Cancers
5. Potential Drug Target For Treating Cocaine Abuse Found
6. Affymetrix and ParAllele Launch Industrys Most Comprehensive Product Line for Targeted Genotyping
7. Targeting a key enzyme with gene therapy reversed course of Alzheimers disease in mouse models
8. Targeted drug delivery achieved with nanoparticle-aptamer bioconjugates
9. Targeted virus compels cancer cells to eat themselves
10. Best of both worlds -- Targeting a single gene could inhibit bone decay and stimulate bone growth
11. Targeting tumors the natural way
Post Your Comments:
(Date:5/17/2013)... (May 18, 2013) The AGA Research Foundation announced ... the relationship between the gut microbiota, one of today,s ... disease. , The AGA Research Awards Panel selected ... Massachusetts General Hospital and Harvard Medical School, Boston, as ... Dr. Chan will receive $25,000 of funding, commencing in ...
(Date:5/17/2013)... the interaction of a group of proteins in the ... identified a new target that could increase cell survival. ... School of Biochemistry and published in the EMBO ... eventually lead to new therapies for stroke and other ... by the team which identified a protein, known as ...
(Date:5/17/2013)... Bethesda, MD The Federation of American Societies for ... of National Institutes of Health (NIH) funding trends highlighting ... to support critical research. The FASEB analysis follows a ... Francis Collins, MD, PhD, who testified that the $1.6 ... to sequestration is "having a substantial impact on the ...
Breaking Biology News(10 mins):New gut microbiome research to explore red meat -- colorectal cancer pathway 2SUMO wrestling cells reveal new protective mechanism target for stroke 2
... 10, 2009)Attempts to treat critical limb ischemia in ... are still thwarted by restenosis (the re-narrowing of ... stenting), the need for repeat treatments and the ... death (gangrene) and amputation. Interventional radiologists have been ...
... Detects Faces in Motion, Matches with Watch-list ... Lithuania, March 9 Neurotechnology, a provider ... the availability of VeriLook Surveillance SDK, a ... using live video streams from high-resolution digital ...
... be tough, but scientists have found a Yellowstone National ... simple one-celled algae called Cyanidioschyzon -- thrives ... occurs naturally around hot springs, said Tim McDermott, professor ... at Montana State University. Cyanidioschyzon could ...
Cached Biology News:Promising 3-year data: Saving limbs with drug-eluting stents 2Promising 3-year data: Saving limbs with drug-eluting stents 3VeriLook Surveillance SDK Provides Real-Time Face Identification Using Video Surveillance Cameras 2VeriLook Surveillance SDK Provides Real-Time Face Identification Using Video Surveillance Cameras 3Montana State team finds Yellowstone alga that detoxifies arsenic 2Montana State team finds Yellowstone alga that detoxifies arsenic 3
(Date:5/21/2013)... Branchburg, NJ (PRWEB) May 21, 2013 ... enhancement industry, has appointed Dale Braddy to Southeastern USA ... proactively bolster its sales muscle in the Southeast. ... a food ingredient brokerage and supplier to food processors ... past 13 years in the food industry and has ...
(Date:5/21/2013)... As the R&D sector becomes ... the industry to deliver better products, faster. Collaborations ... companies often means turning big ideas into reality, ... collaboration with Sensidose AB and Recipharm, is one ... to market sooner. The partnership resulted in the ...
(Date:5/21/2013)... May 21, 2013  Synthetic Biologics, Inc. (NYSE MKT: SYN), ... of serious infectious diseases, announced today that Jeffrey ... Annual Marcum LLP MicroCap Conference on Thursday, May 30, ... the Grand Hyatt Hotel. Mr. Riley is scheduled to present ... of Synthetic Biologics, presentation can be accessed by logging onto ...
(Date:5/21/2013)... NANONEX CORPORATION, a pioneer and leading company ... successful delivery and installation of a new nanoimprint ... major Japanese manufacturing company. , ... lithography tool that has the ability to process ... types. Based on Nanonex inventions and proprietary technologies, ...
Breaking Biology Technology:The Development of an Innovative Microtablet Dosage Form, a Success Story: Live Webinar Hosted by Xtalks 2Synthetic Biologics to Present at the 2nd Annual Marcum LLP MicroCap Conference 2Nanonex Announces the Shipment and Installation of an Innovative Nanoimprint Lithography System for Fully Automated Manufacturing 2
... BOULDER, Colo., and IPSWICH, Mass., July 27, ... Biolabs, Inc. (NEB) announce today that they ... whereby SomaLogic will provide specific SOMAmers as ... and future NEB nucleic acid amplification and ...
... July 27, 2011 Cadence Pharmaceuticals, Inc. (NASDAQ: ... and commercializing proprietary products principally for use in the hospital ... ended June 30, 2011 financial results on Wednesday, August 3, ... call and live webcast to discuss the financial results on ...
... Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX ) today ... registration trial of KRX-0401 (perifosine) for the treatment of ... over 430 randomized patients, is being conducted pursuant to ... Drug Administration (FDA) and with Fast-Track Designation.  Perifosine is ...
Cached Biology Technology:Agreement Between SomaLogic and New England Biolabs Enables the Use of SOMAmer Technology for the Optimization of Multiple PCR Products 2Keryx Biopharmaceuticals Announces Completion of Patient Enrollment in KRX-0401 (Perifosine) Phase 3 Refractory Advanced Colorectal Cancer Study 2Keryx Biopharmaceuticals Announces Completion of Patient Enrollment in KRX-0401 (Perifosine) Phase 3 Refractory Advanced Colorectal Cancer Study 3Keryx Biopharmaceuticals Announces Completion of Patient Enrollment in KRX-0401 (Perifosine) Phase 3 Refractory Advanced Colorectal Cancer Study 4Keryx Biopharmaceuticals Announces Completion of Patient Enrollment in KRX-0401 (Perifosine) Phase 3 Refractory Advanced Colorectal Cancer Study 5